Long-term efficacy and safety of subcutaneous pasireotide alone or in combination with cabergoline in Cushing's disease. - Feelders RA; Fleseriu M; Kadioglu P; Bex M; González-Devia D; Boguszewski CL; Yavuz DG; Patino H; Pedroncelli AM; Maamari R; Chattopadhyay A; Biller BMK; et al. (Frontiers in endocrinology, 2023)